MaaT Pharma Announces Update on U.S. FDA Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease

LYON, France--(BUSINESS WIRE)---- $MAAT--MaaT Pharma (EURONEXT: MAAT – the “Company”), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, today announced that it received a communication from the U.S. Food and Drug Administration (“FDA” or “the Agency”) related to the Company’s Investigational New Drug (IND) application filed in June 2021 to initiate in the U.S. an open-label, single